A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 14, 2025

Study Completion Date

November 14, 2025

Conditions

Recurrent Glioblastoma

Interventions

DRUG

Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection

Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule

All Listed Sponsors

collaborator

Beijing DCTY Biotech Co.,Ltd.

OTHER

lead

Beijing Tsinghua Chang Gung Hospital

OTHER

NCT05802693 - A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma | Biotech Hunter | Biotech Hunter